+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-Term Statin Administration Does Not Affect Warfarin Time in Therapeutic Range in Australia or Singapore



Long-Term Statin Administration Does Not Affect Warfarin Time in Therapeutic Range in Australia or Singapore



Journal of Clinical Medicine 7(5):



Warfarin requires ongoing monitoring of the International Normalised Ratio (INR). This is because numerous factors influence the response, including drug interactions with commonly-prescribed medications, such as statins. The administration of statins with warfarin may change INR; however, there is limited information regarding the effects on warfarin control as measured by time in therapeutic range (TTR). Statins may also alter bleeds with warfarin, but there are conflicting reports demonstrating both increased and decreased bleeds, and limited data on diverse ethnic populations. Therefore, the aim of this study was to determine the effect of statin administration on warfarin control and bleeds in patients in Australia and Singapore. Retrospective data were collected for patients on warfarin between January and June 2014 in Australia and Singapore. Patient data were used to calculate TTR and bleed events. Concurrent statin therapy was assessed and comparisons of TTR and bleed incidence were made across patient subgroups. Warfarin control in Australia and Singapore was not significantly affected by statins, as measured by TTR (83% and 58%, respectively), frequency of testing, and warfarin doses. In Australia, statin use did not significantly affect bleeds, whilst in Singapore the bleed incidence was significantly lower for patients on statins. Chronic concurrent administration of statins with warfarin does not adversely affect warfarin TTR in Australia or Singapore. In Singapore, patients on statins, compared to no statins, had a lower bleed incidence and this requires further investigation, especially given the potential genetic influences of ethnicity on both statin and warfarin metabolism.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065288641

Download citation: RISBibTeXText

PMID: 29723987

DOI: 10.3390/jcm7050097


Related references

Analysis of factors affecting time in therapeutic range control after warfarin administration. Die Pharmazie 70(7): 494-498, 2015

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children. Journal of Thrombosis and Haemostasis 9(5): 1090-1092, 2011

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2331-2332, 2012

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2332-2333, 2012

The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatolian Journal of Cardiology 16(8): 595-600, 2016

The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. Balkan Medical Journal 34(4): 349-355, 2017

Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy. Clinical Pharmacy 6(6): 492-495, 1987

Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?. Journal of Clinical Pharmacy and Therapeutics 37(4): 375-377, 2012

Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm 11(12): 2206-2213, 2014

Relationship between time spent at extreme International Normalized Ratios and time in therapeutic range with bleeding and thrombosis in warfarin-treated patients. American Journal of Health-System Pharmacy 72(14): 1188-1194, 2015

Warfarin dosing by genotype did not improve time in therapeutic range. Annals of Internal Medicine 160(6): Jc8, 2014

Improvement of time in therapeutic range with warfarin by pharmaceutical intervention. International Journal of Clinical Pharmacy 39(1): 41-44, 2017

NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter?. Recent Advances in Cardiovascular Drug Discovery 10(1): 60-64, 2015

Evaluating time in therapeutic range for hemodialysis patients taking warfarin. Clinical Nephrology 83(2): 80-85, 2015

Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation. Oncotarget 7(34): 54194-54199, 2016